Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have received an average rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $343.00.

A number of analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $334.00 target price on the stock in a research note on Monday, June 25th. Barclays started coverage on Bio-Rad Laboratories in a report on Wednesday, September 5th. They issued an “equal weight” rating and a $345.00 price target for the company. Jefferies Financial Group upped their price target on Bio-Rad Laboratories from $325.00 to $355.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Finally, Morgan Stanley started coverage on Bio-Rad Laboratories in a report on Thursday, September 20th. They issued an “equal weight” rating and a $335.00 price target for the company.

Shares of BIO stock traded up $6.37 during trading hours on Friday, reaching $281.68. 165,569 shares of the stock were exchanged, compared to its average volume of 150,268. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.17 and a current ratio of 4.50. Bio-Rad Laboratories has a 12-month low of $214.44 and a 12-month high of $345.15. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of 68.70, a PEG ratio of 3.27 and a beta of 0.96.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Tuesday, August 7th. The medical research company reported $1.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.37. Bio-Rad Laboratories had a net margin of 44.77% and a return on equity of 4.23%. The firm had revenue of $575.91 million for the quarter, compared to analyst estimates of $551.05 million. Equities analysts forecast that Bio-Rad Laboratories will post 6.38 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Mason Street Advisors LLC boosted its holdings in Bio-Rad Laboratories by 1.9% in the first quarter. Mason Street Advisors LLC now owns 10,153 shares of the medical research company’s stock valued at $2,539,000 after purchasing an additional 194 shares in the last quarter. Xact Kapitalforvaltning AB boosted its holdings in Bio-Rad Laboratories by 7.8% in the second quarter. Xact Kapitalforvaltning AB now owns 2,772 shares of the medical research company’s stock valued at $800,000 after purchasing an additional 200 shares in the last quarter. TLP Group LLC boosted its holdings in Bio-Rad Laboratories by 15.3% in the first quarter. TLP Group LLC now owns 1,764 shares of the medical research company’s stock valued at $441,000 after purchasing an additional 234 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in Bio-Rad Laboratories by 1.8% in the second quarter. Public Employees Retirement System of Ohio now owns 13,631 shares of the medical research company’s stock valued at $3,933,000 after purchasing an additional 246 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its holdings in Bio-Rad Laboratories by 2.6% in the first quarter. Great West Life Assurance Co. Can now owns 11,886 shares of the medical research company’s stock valued at $2,974,000 after purchasing an additional 300 shares in the last quarter. 63.22% of the stock is owned by hedge funds and other institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Read More: Why do companies issue stock splits?

Analyst Recommendations for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.